Clinical trial
A Study Of GW679769 Compared To Placebo In Women With Overactive Bladder
NCT00321477 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00321477 |
|---|---|
| Title | A Study Of GW679769 Compared To Placebo In Women With Overactive Bladder |
| Official title | NK1 Receptor Antagonist vs Placebo in the Treatment of Overactive Bladder Symptoms |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Incontinence, Urinary and Urinary Bladder, Overactive, Overactive Bladder |
| Intervention type | Drug |
| Interventions | GW679769 oral tablets |
| Enrollment | 160 |
| Start date | Dec 1, 2005 |
| Primary completion | Feb 1, 2007 |
| Completion | Feb 1, 2007 |
| First posted | May 3, 2006 |
| Last update posted | Jan 20, 2017 |
| Countries | Canada, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: